imuno™ Treatment - The Science
Treatment with imuno™
imuno™ is a novel type of immune supporting compound that targets the innate immune system. At variance with other immune stimulating molecules like GcMAF that target only one type of cells (e.g. macrophages), Imuno™ targets all cells of the innate immune system and, because of this, helps to direct the adaptive immune system against cancer cells, cells infected by viruses, cells harboring abnormal proteins or pathogens.
imuno™ is based on the non-covalent, multi-molecular assembly of three components with known healthy properties that are assembled through a novel proprietary procedure. One of the major novelties of Imuno™ that sets it apart from all other immune stimulating approaches is the use of a novel type of low-molecular weight vegan chondroitin sulfate (LMW-CS), a glycosaminoglycan that is endowed with a number of healthy properties ranging from anti-inflammatory to anti-viral, neuro-protecting, and immune stimulating.
The healthy properties of CS have been described in a number of peer-reviewed papers and it is known that CS contains the active site of GcMAF (the moiety N-acetylgalactosamine). Even better, LMW-CS has demonstrated clinical activity much higher than the best animal-derived unfractionated CS.
The other two components of imuno™, Vitamin D3, and phosphatidylcholine (PC) are endowed with a number of healthy properties that are amplified by the multi-molecular assembly occurring in Imuno™.
The original proprietary procedure enables non-covalent binding of PC to LMW-CS thanks to the sulfation pattern of LMW-CS that is distributed on a higher number of molecules as compared with that of unfractionated CS, thus allowing a higher number of electrostatic interactions. Such a feature is not present in any other compound based on unfractionated CS.
Vitamin D3, being a lipophilic molecule of small size, is intercalated in the structures constituted by PC and LMW-CS is a manner similar to the assembly in cell membranes.
The multi-molecular assembly described above, favors bio-availability of all the ingredients of the Imuno™ formula thus amplifying the known healthy properties of each one with particular reference to immune system modulation as well as anti-inflammatory, anti-cancer and neuroprotective properties. The proprietary procedure of manufacture brings the further advantage of the formation of nano-emulsions. It is well assessed that nano-particulate delivery systems offer plenty of advantages over conventional dosage forms which include improved efficacy, reduced toxicity, enhanced biodistribution and improved patient compliance.
imuno™ Dosage Recommendations
Shake well before use and imuno™ has a blood thinning effect similar to heparin, so should not be taken by people on anticoagulant drugs unless under medical supervision.
- Stage 1, 2, & 3: 0.2ml (4 drops) per day.
- Stage 4: 0.5ml per day.
- Late Stage 4: 1ml every other day OR every day if needed.
Autism, Chronic Fatigue, Multiple Sclerosis
- Start with 0.1ml (2 drops) every 3 days.
- Gradually increase or reduce dose, as tolerated, to create desired effect.
- Maximum dose for these individuals may be only up to 0.3ml every 3 days.
History of imuno™
Molecular Biologist, Dr Marco Ruggiero, MD. Ph.D., whilst working at the National Cancer Institute of the NIH in Maryland, worked on Macrophage Stimulating Factor (CSF-1) and human cancer from 1990, which is four years before Dr Yamamoto coined the acronym GcMAF. (Pierce JH, 1990 Aug, Proceedings of the National Academy of Sciences USA, 5613–5617)
Rerum® was conceived in 2015 by the same Dr Marco Ruggiero. Rerum® was superior to GcMAF in that it was nanosized and more stable (kept better) than GcMAF.
imuno™ for superior immune support was conceived in 2018 by the same Dr Marco Ruggiero.
Safety of imuno™
Being pH neutral and sterile also means imuno™ is safe to use in all the ways that your doctor may prescribe.
Ruggiero M, Pacini S, (2018 Sep 27). Rationale for the design of a novel tool for immunotherapy based on an emulsion of glycosaminoglycan.